Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
Details for the presentation are as follows:
Session: Seeking Improved Therapeutics for Wet AMD & DME Patients
Title: Enhancing the Standard of Care in Wet AMD, BRVO, & DME
Presenter: Russ Trenary, President and CEO,
Date and Time: Wednesday, April 6, 2022, 9:45 AM EST
For more information, please visit wet-amd-drugdevelopment.com.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg), an investigational therapy, as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD. The submission is supported by Outlook Therapeutics’ wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com
Investor Inquiries:
Chief Executive Officer
T: 833.475.8247
OTLK@jtcir.com
Source: Outlook Therapeutics, Inc.
